相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy
Ila Tamaskar et al.
JOURNAL OF UROLOGY (2008)
VEGF Inhibition and Renal Thrombotic Microangiopathy
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF inhibition and renal thrombotic microangiopathy
Vera Eremina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
p53 gene and protein status:: The role of p53 alterations in predicting outcome in patients with bladder cancer
Ben George et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
E. Kapiteijn et al.
ANNALS OF ONCOLOGY (2007)
Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers
D. J. George et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pre-eclampsia: Clinical manifestations and molecular mechanisms
Suzanne Baumwell et al.
NEPHRON CLINICAL PRACTICE (2007)
Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group
Luigi Schips et al.
EUROPEAN UROLOGY (2007)
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
Richard J. Levine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Circulating angiogenic factors and the risk of preeclampsia
RJ Levine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The von Hippel-Lindau tumor suppressor gene and kidney cancer
WG Kaelin
CLINICAL CANCER RESEARCH (2004)
Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma
B Ljungberg et al.
UROLOGICAL RESEARCH (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma
J Jacobsen et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
J Jacobsen et al.
JOURNAL OF UROLOGY (2000)
分享论文
